F S&P 500
5,080.25 +33.75 (+0.67%) F Dow Jones
38,258.00 +189.00 (+0.50%) F Nasdaq
17,578.75 +140.50 (+0.81%) E-mini Russell 2000 Index Futur
2,013.30 +23.60 (+1.19%) Petróleo
79.17 +0.17 (+0.22%) Oro
2,305.20 -5.80 (-0.25%)
Agios Pharmaceuticals, Inc. (AGIO)
Antes de la apertura del mercado:
Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 383
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Brian M. Goff M.B.A. | CEO & Director | 1.46M | N/D | 1969 |
| Ms. Cecilia Jones | Chief Financial Officer | 751.48k | N/D | 1975 |
| Mr. James William Burns | Corporate Secretary & Chief Legal Officer | 1.02M | N/D | 1978 |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research & Development | 1.25M | N/D | 1980 |
Descripción
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Agios Pharmaceuticals, Inc. a partir del 29 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 5; Junta: 2; Derechos del accionista: 7; Compensación: 6.
